Breast Cancer PDX Models

Bring clarity to your research with our collection of highly characterized, deeply sequenced, patient-derived xenografts for breast cancer.

Horizon is excited to exclusively offer the largest collection of highly characterized patient-derived xenograft (PDX) models of breast cancer available today. The WHIM (Washington University Human-in-Mouse) collection has been developed by Shunqiang Li and Matthew Ellis at Washington University and published in Cell Reports. This breast cancer PDX collection has undergone whole genome sequencing (WGS), with care to remove contaminating mouse signal. Additionally, WGS has been performed on the originating tumors, early and late passages of PDX, demonstrating striking similarity and faithful modeling of the original tumor. These PDX models are implanted as dissociated cells into immunodeficient mouse models which may then be used for in vivo efficacy studies.

Horizon offers this collection as ungrafted PDX heterogeneous cell suspensions for use in your facility. Additionally, Horizon offers a number of services around the WHIM breast cancer PDX collection, including in vivo efficacy studies and ex vivo proliferation studies. For services, consult with our team of expert scientists to design your study, provide us with your test articles, and then our team of highly trained staff will demonstrate the effect of your test article on PDX grown in immunodeficient mice.

This collection comprises a broad range of breast cancer PDX models, including ER+ models, triple-negative models, and HER2+ models. This allows the study of different types of human breast cancer tumors in an in vivo model system, and represents a key tool in the development of personalized medicines. These models accurately model real patient tumors, enabling researchers to discover important genetic differences, develop biomarkers to distinguish these variations, and ultimately develop patient-specific therapies.

SAGE® Breast Cancer Patient-Derived Xenografts from Washington University:

  • Nearly 25 PDX models of breast cancer
  • 8 ER+ PDX models, 2 HER2+ PDX models, and 12 triple negative breast cancer (TNBC) PDX models
  • Whole genome sequencing of original tumor, early passage PDX, and late passage PDX
  • Comprehensive patient histories
  • RNAseq profiles
  • DNA microarrays
  • Estradiol responsiveness data

WashU Breast Cancer PDX Heat Map

Figure 1. Microarray showing PAM50 subtype. The colors of the array tree and the squares below the tree denote the subtype call of each sample. Red, basal-like; pink, HER2-enriched; dark blue, luminal A; light blue, luminal B; yellow, Claudin-low.

Source: Li, Shunqiang et al. Cell Reports, Volume 4, Issue 6, 1116 - 1130

Click here to browse the collection

 

Back to top